NASDAQ:VRNA - Nasdaq - US9250501064 - ADR - Currency: USD
VRNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. While VRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, VRNA is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -31.17% | ||
ROE | -72.35% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 33.49% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.07 | ||
Debt/FCF | N/A | ||
Altman-Z | 11.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.86 | ||
Quick Ratio | 8.73 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 39.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
77.49
+3.56 (+4.82%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 39.98 | ||
P/S | 55.58 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 29.07 | ||
P/tB | 29.14 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -31.17% | ||
ROE | -72.35% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 33.49% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.07 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 100.83% | ||
Cap/Sales | 0.93% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.86 | ||
Quick Ratio | 8.73 | ||
Altman-Z | 11.43 |